HardCardiologyHeart failure with reduced ejection fraction and SGLT2 inhibitor useau-racpau-amc
A 68-year-old man with heart failure with reduced ejection fraction (LVEF 30%) and type 2 diabetes is stable on maximally tolerated ACE inhibitor, beta blocker and mineralocorticoid receptor antagonist. His estimated glomerular filtration rate is 65 mL/min/1.73 m2 and potassium 4.8 mmol/L. According to contemporary Australian consensus, which additional class of medicine would provide further prognostic benefit?